Eli Lilly (SNSE:LLYCL) - Stock Price, News & Analysis

LLYCL Stock Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. More details

LLYCL fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	4/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 35.7% below our estimate of its fair value

Earnings are forecast to grow 29.22% per year

Earnings grew by 67.8% over the past year

Analysts in good agreement that stock price will rise by 32.3%

Risk Analysis

Debt is not well covered by operating cash flow

High level of non-cash earnings

Highly volatile share price over the past 3 months compared to the CL market

Eli Lilly and Company Competitors

Novo Nordisk

CPSE:NOVO B

DKK 3.2t

Johnson & Johnson

NYSE:JNJ

US$368.6b

Merck

NYSE:MRK

US$246.5b

AstraZeneca

LSE:AZN

UK£156.0b

Price History & Performance

Summary of all time highs, changes and price drops for Eli Lilly
Historical stock prices
Current Share Price	US$727,465.00
52 Week High	US$878,500.00
52 Week Low	US$692,320.00
Beta	0.43
11 Month Change	-15.16%
3 Month Change	-16.04%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-4.47%

Recent updates

Shareholder Returns

	LLYCL	CL Pharmaceuticals	CL Market
7D	-10.0%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how LLYCL performed against the CL Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how LLYCL performed against the CL Market.

Price Volatility

Is LLYCL's price volatile compared to industry and market?
LLYCL volatility
LLYCL Average Weekly Movement	4.9%
Pharmaceuticals Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in CL Market	0%
10% least volatile stocks in CL Market	0%

Stable Share Price: LLYCL's share price has been volatile over the past 3 months compared to the CL market.

Volatility Over Time: Insufficient data to determine LLYCL's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1876	43,000	Dave Ricks	www.lilly.com

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.

Eli Lilly and Company Fundamentals Summary

How do Eli Lilly's earnings and revenue compare to its market cap?
LLYCL fundamental statistics
Market cap	CL$660.76t
Earnings (TTM)	CL$8.15t
Revenue (TTM)	CL$39.80t

80.7x

P/E Ratio

16.5x

P/S Ratio

Is LLYCL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LLYCL income statement (TTM)
Revenue	US$40.86b
Cost of Revenue	US$7.80b
Gross Profit	US$33.06b
Other Expenses	US$24.69b
Earnings	US$8.37b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	9.30
Gross Margin	80.91%
Net Profit Margin	20.48%
Debt/Equity Ratio	218.1%

How did LLYCL perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

54%

Payout Ratio

Does LLYCL pay a reliable dividends?

See LLYCL dividend history and benchmarks

When do you need to buy LLYCL by to receive an upcoming dividend?
Eli Lilly dividend dates
Ex Dividend Date	Nov 15 2024
Dividend Pay Date	Dec 10 2024
Days until Ex dividend	7 days
Days until Dividend pay date	18 days

Does LLYCL pay a reliable dividends?

See LLYCL dividend history and benchmarks

LLYCL Stock Overview

Rewards

Risk Analysis

Eli Lilly and Company Competitors

CPSE:NOVO B

DKK 3.2t

NYSE:JNJ

US$368.6b

NYSE:MRK

US$246.5b

LSE:AZN

UK£156.0b

Price History & Performance

Recent News & Updates

Frantz Law Group Files Oceanside Unified School District Lawsuit Against Eli Lily, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark, and Optum RX for Insulin Pricing Scheme

Eli Lilly and Company Announces Board Changes

Eli Lilly and Company Announces Positive Phase 2 Results for muvalaplin

Eli Lilly and Company Announces Detailed Results from the Phase 3 Survey-1 Three-Year Study

Eli Lilly and Company Announces Details of Presentations At the 2024 American Society of Hematology Annual Meeting

Third quarter dividend of US$1.30 announced

Recent updates

Frantz Law Group Files Oceanside Unified School District Lawsuit Against Eli Lily, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark, and Optum RX for Insulin Pricing Scheme

Eli Lilly and Company Announces Board Changes

Eli Lilly and Company Announces Positive Phase 2 Results for muvalaplin

Eli Lilly and Company Announces Detailed Results from the Phase 3 Survey-1 Three-Year Study

Eli Lilly and Company Announces Details of Presentations At the 2024 American Society of Hematology Annual Meeting

Third quarter dividend of US$1.30 announced

Eli Lilly and Company to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium

Third quarter 2024 earnings released: EPS: US$1.08 (vs US$0.064 loss in 3Q 2023)

Eli Lilly and Company Revises Earnings Guidance for the Year 2024

Lilly's Mirikizumab Is First and Only IL23p19 Antagonist to Report Long-Term, Multi-Year, Sustained Efficacy and Safety Data for Both Ulcerative Colitis and Crohn's Disease

Eli Lilly and Company Declares Fourth-Quarter 2024 Dividend, Payable on December 10, 2024

Lilly's EBGLYSS (Lebrikizumab-Lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab

Eli Lilly and Company to Report Q3, 2024 Results on Oct 30, 2024

Eli Lilly and Company Reports One-Year Histologic Outcomes in Phase 3 Study of Mirikizumab Compared to Ustekinumab for Crohn's Disease

Eli Lilly and Company Appoints Thomas J. Fuchs as First Chief AI Officer, Effective October 21, 2024

FDA Approves Lilly's EBGLYSS (Lebrikizumab-Lbkz) for Adults and Children 12 Years and Older with Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Positive Topline Results from the QWINT-1 and QWINT-3 Phase 3 Clinical Trials Evaluating Once Weekly Insulin Efsitora Alfa

Eli Lilly and Company Announces Positive Topline Results from the Surmount-1 Three-Year Study Evaluating the Efficacy and Safety of Tirzepatide

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

Second quarter 2024 earnings released: EPS: US$3.29 (vs US$1.96 in 2Q 2023)

Eli Lilly and Company Raises Earnings Guidance Full-Year 2024

Insufficient new directors